BIOMAT Database Logo BIOMAT Database Logo

Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. 1996

A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Department of Anesthesia and Intensive Care, University La Sapienza, Rome, Italy.

Cardiopulmonary bypass (CPB) increases risk of postoperative bleeding and need for transfusion. The aim of this study was to evaluate the effects of aprotinin, epsilon aminocaproic acid and tranexamic acid on coagulation patterns and need for banked blood transfusion. Ninety-six consecutive patients who underwent coronary artery bypass surgery were randomly assigned to 4 groups (24 patients each). The following parameters were monitored before, during and after CPB: activated lotting time, hemoglobin, prothrombin time, activated prothromboplastin time, fibrinogen, antithrombin III, xDP, Factor VIII, Thrombin-Antithrombin Complex and plasminogen. Analysis of postoperative bleeding and need for transfusion showed that the aprotinin group had significantly lower mediastinal bleeding. Transfused patients were 2, 4, 12 and 18 respectively in the aprotinin, epsilon aminocaproic acid, tranexamic acid and placebo treated group. In conclusion the use of protease inhibitors significantly reduces postoperative bleeding and transfusion. The aprotinin-treated group had the lower need for transfusion.

UI MeSH Term Description Entries
D007611 Aprotinin A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) BPTI, Basic Pancreatic Trypsin Inhibitor,Basic Pancreatic Trypsin Inhibitor,Bovine Kunitz Pancreatic Trypsin Inhibitor,Kallikrein-Trypsin Inactivator,Kunitz Pancreatic Trypsin Inhibitor,Trypsin Inhibitor, Basic, Pancreatic,Trypsin Inhibitor, Kunitz, Pancreatic,Antilysin,Bovine Pancreatic Trypsin Inhibitor,Contrical,Contrykal,Dilmintal,Iniprol,Kontrikal,Kontrykal,Pulmin,Traskolan,Trasylol,Zymofren,Inactivator, Kallikrein-Trypsin,Kallikrein Trypsin Inactivator
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D005260 Female Females
D006490 Hemostatics Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. Antihemorrhagic,Hemostatic,Antihemorrhagics
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001026 Coronary Artery Bypass Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion. Aortocoronary Bypass,Bypass, Coronary Artery,Bypass Surgery, Coronary Artery,Coronary Artery Bypass Grafting,Coronary Artery Bypass Surgery,Aortocoronary Bypasses,Artery Bypass, Coronary,Artery Bypasses, Coronary,Bypass, Aortocoronary,Bypasses, Aortocoronary,Bypasses, Coronary Artery,Coronary Artery Bypasses

Related Publications

A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid.
January 1995, International anesthesiology clinics,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit.
August 2001, The Annals of thoracic surgery,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
A Review of Post--Cardiopulmonary Bypass Bleeding, Aminocaproic Acid, Tranexamic Acid, and Aprotinin.
December 1996, American journal of therapeutics,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Comparison of intraoperative tranexamic acid and epsilon-aminocaproic acid in cardiopulmonary bypass patients.
September 2020, JTCVS open,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Tranexamic acid reduces bleeding after cardiopulmonary bypass when compared to epsilon aminocaproic acid and placebo.
January 1997, Journal of cardiac surgery,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Epsilon-aminocaproic acid for bleeding after cardiopulmonary bypass.
June 1971, The Annals of thoracic surgery,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Tranexamic acid reduces blood loss after cardiopulmonary bypass.
January 1993, ASAIO journal (American Society for Artificial Internal Organs : 1992),
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Epsilon-aminocaproic acid, neonates, and cardiopulmonary bypass.
March 2011, Anesthesia and analgesia,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial.
January 2004, Current medical research and opinion,
A Menichetti, and L Tritapepe, and G Ruvolo, and G Speziale, and A Cogliati, and C Di Giovanni, and M Pacilli, and A Criniti
Co-administration of aprotinin and epsilon-aminocaproic acid during cardiopulmonary bypass in a swine model.
December 2000, The journal of extra-corporeal technology,
Copied contents to your clipboard!